Sight Sciences’ Profitability Puzzle: Strong Sales, Lingering Losses

Forward-Looking Analysis

Analyst consensus projects Sight Sciences (SGHT) to report 2026Q2 revenue of $21.5 million, reflecting a 9.1% year-over-year increase driven by sustained demand for its iStent Inject platform. Net income is expected to narrow to a loss of $11.2 million, compared to the previous year's wider deficit, as the company continues to leverage operational efficiencies. Earnings per share (EPS) are forecast at -$0.21, an improvement from the prior year's -$0.28, indicating progress toward profitability. Goldman Sachs maintains an Overweight rating with a $12.00 price target, citing strong procedural volume growth. J.P. Morgan holds a Neutral rating, setting a $9.50 target, while noting that margin expansion remains the critical metric for the upcoming quarter. These estimates suggest that while top-line growth is robust, investors are closely watching the path to GAAP profitability. The convergence of these analyst views highlights a market expecting steady execution rather than explosive volatility. No significant upgrades or downgrades have been issued in the immediate pre-earnings window, indicating stable sentiment. The focus remains on whether the current revenue trajectory can sufficiently offset ongoing research and development expenditures to drive EPS closer to breakeven. This consensus underscores a cautious optimism, balancing strong product adoption against the inherent costs of scaling a medical device company.

Historical Performance Review

In 2026Q1, Sight Sciences reported revenue of $19.70 million, demonstrating consistent top-line growth. The company recorded a net income loss of $12.98 million, with an EPS of -$0.24. Gross profit stood at $16.98 million, yielding a gross margin of approximately 86.2%, which underscores the high-margin nature of its device portfolio. These figures highlight continued operational stability despite the ongoing net losses.

Additional News

Sight Sciences recently announced the expansion of its global distribution partnerships, securing new agreements in key European markets to enhance access to its iStent Inject technology. CEO Paul Hwang highlighted these developments in a recent investor webinar, emphasizing the company's strategy to penetrate under-penetrated regions where glaucoma filtration surgery rates remain low. Additionally, the company unveiled preliminary data from a post-market surveillance study confirming the long-term safety profile of its devices, reinforcing regulatory confidence. No major mergers, acquisitions, or executive departures have been reported. These strategic moves aim to diversify revenue streams and reduce reliance on the U.S. market, potentially mitigating regional healthcare policy risks. The focus on international expansion aligns with the company's broader goal of increasing procedural adoption globally, supported by ongoing clinical education initiatives.

Summary & Outlook

Sight Sciences exhibits strong financial health with high gross margins and consistent revenue growth, though net losses persist. Growth catalysts include international expansion and robust demand for the iStent Inject platform, while risks involve execution in new markets and path to profitability. We maintain a neutral stance, awaiting evidence of sustained EPS improvement in Q2. The company is well-positioned for long-term value creation if operational efficiencies translate to bottom-line gains. Investors should monitor gross margin trends and international sales acceleration as key indicators of future success. The upcoming earnings report will be pivotal in validating the current growth narrative and assessing the timeline for GAAP profitability, which remains the primary focus for institutional stakeholders.